Huntsman Q3 2026: Modest Improvement, But Cyclical Trough Persists

What happened

Huntsman's Q3 2026 earnings show a modest improvement over the prior-year period, with adjusted net income of $7 million versus an adjusted net loss of $5 million a year ago. On a GAAP basis, the company still reported a net loss of $18 million, though that is narrower than the $25 million loss in Q3 2025. This incremental progress aligns with the broader thesis that Huntsman is navigating an 'extended cyclical trough' while executing on cost reductions and portfolio shifts toward higher-value PU systems and advanced materials, as captured in the latest deep value report. Despite the improved adjusted profitability, the core challenges identified in the report remain: elevated net debt/EBITDA around 5.8x, negative interest coverage, and a stock that still trades well above a conservative DCF estimate of ~$6.3 per share (as of late 2025). The third quarter does not alter the fundamental picture of a deeply cyclical business still awaiting a clear margin recovery, but it provides some initial evidence that cost actions and modest pricing stabilization are beginning to flow through.

Implication

Huntsman's Q3 2026 results, with adjusted net income turning positive for the first time in several quarters, suggest that the company's restructuring efforts and cost savings are beginning to offset weak pricing, but the magnitude of improvement is too small to signal a durable earnings recovery. The prior deep value report highlighted a lack of margin of safety versus conservative DCF (~$6.3 vs. ~$10.4 stock price) and elevated leverage, and these concerns remain intact despite the better-than-expected adjusted figure. Free cash flow generation has been positive, providing some balance sheet support, but interest coverage is still negative, and the extended cyclical trough in chemicals continues to pressure segment margins. Investors should focus on whether positive adjusted earnings can be sustained over multiple quarters and whether pricing stabilizes or improves, as a clear trend would warrant a more constructive view. Until then, the risk/reward remains unattractive at current levels, and the stock is better suited for monitoring rather than aggressive positioning.

Thesis delta

The core WAIT stance remains intact: the Q3 2026 adjusted net income of $7 million is a slight positive but not enough to overcome the lack of margin of safety versus the ~$6.3 DCF anchor and still-elevated leverage. However, the return to positive adjusted earnings, even if marginal, slightly reduces the risk of immediate financial distress and warrants watching for a sequence of improving quarters. A clear trend of margin recovery could eventually move the stance toward a potential buy at lower prices, while stagnation would reinforce the wait.